Synvista Therapeutics, Inc.
SYNI
$0.00
$0.000.00%
| 09/30/2008 | 06/30/2008 | ||||
|---|---|---|---|---|---|
| Revenue | -98.45% | 2,250.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -98.45% | 2,250.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -98.45% | 2,250.00% | |||
| SG&A Expenses | 9.67% | 23.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.59% | 6.07% | |||
| Operating Income | -7.57% | -4.18% | |||
| Income Before Tax | 5.79% | -22.98% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.79% | -22.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.79% | -22.98% | |||
| EBIT | -7.57% | -4.18% | |||
| EBITDA | -7.59% | -4.17% | |||
| EPS Basic | 3.36% | -12.17% | |||
| Normalized Basic EPS | -8.43% | -6.84% | |||
| EPS Diluted | 3.36% | -12.17% | |||
| Normalized Diluted EPS | -8.43% | -6.84% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
